Virpax Pharmaceuticals, Inc.
VRPXDelisted Jul 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001708331
Virpax Pharmaceuticals, Inc. was delisted on Jul 21, 2025; its insiders filed their last Form 4 on Jul 10, 2024; 7 institutions reported holding it in 13F filings for Q1 2025, worth $34.9K in total; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in Virpax Pharmaceuticals, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +5 vs. Q3 2023
- Shares held
- 377.2K
- −239.5K (−38.8%) vs. Q3 2023
- Total value
- $120.5K
- −$372.9K (−75.6%) vs. Q3 2023
- New holders
- 6
- 5 more added
- Sold out
- 1
- 1 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRPX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 1 | $2 |
| Q1 2025 | 7 | $34.9K |
| Q4 2024 | 12 | $46.7K |
| Q3 2024 | 9 | $66.8K |
| Q2 2024 | 8 | $12.6K |
| Q1 2024 | 6 | $6.44K |
| Q4 2023 | 18 | $120.5K |
| Q3 2023 | 13 | $493.4K |
| Q2 2023 | 14 | $827.7K |
| Q1 2023 | 17 | $873.8K |
| Q4 2022 | 21 | $973.0K |
| Q3 2022 | 16 | $2.17M |
| Q2 2022 | 16 | $3.13M |
| Q1 2022 | 16 | $3.29M |
| Q4 2021 | 18 | $7.67M |
| Q3 2021 | 13 | $11.4M |
| Q2 2021 | 7 | $1.12M |
| Q1 2021 | 5 | $1.29M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Virpax Pharmaceuticals, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| The PNC Financial Services Group, Inc. | 100,875 | $32.3K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 66,294 | $21.2K | 0.00% | +1,149+1.8% | Added |
| Geode Capital Management, LLC | 63,928 | $20.2K | 0.00% | 00.0% | Unchanged |
| Sheets Smith Wealth Management | 50,000 | $16.0K | 0.00% | +50,000 | New |
| Renaissance Technologies LLC | 30,500 | $10.0K | 0.00% | −40,600−57.1% | Reduced |
| Susquehanna International Group, LLP | 17,734 | $5.59K | 0.00% | +17,734 | New |
| Northern Trust Corp | 15,221 | $4.87K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 11,695 | $3.74K | 0.00% | +11,695 | New |
| UBS Group AG | 6,616 | $2.12K | 0.00% | +6,498+5,506.8% | Added |
| Tower Research Capital LLC (TRC) | 6,318 | $2.02K | 0.00% | +98+1.6% | Added |
| JPMorgan Chase & Co | 4,358 | $1.37K | 0.00% | +4,358 | New |
| Advisor Group Holdings, Inc. | 2,400 | $768 | 0.00% | +1,800+300.0% | Added |
| Signature Resources Capital Management, LLC | 500 | $160 | 0.00% | +500 | New |
| BlackRock Inc. | 464 | $149 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 150 | $48 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 67 | $21 | 0.00% | +4+6.3% | Added |
| Parallel Advisors, LLC | 14 | $5 | 0.00% | +14 | New |
| Hantz Financial Services, Inc. | 100 | $0 | 0.00% | 00.0% | Unchanged |
| Sabby Management, LLC | 0 | $0 | 0.00% | −292,790−100.0% | Sold out |